How should unconjugated hyperbilirubinemia be managed?

Management of Unconjugated Hyperbilirubinemia

Phototherapy is the primary treatment for unconjugated hyperbilirubinemia in newborns ≥35 weeks gestation, initiated when total serum bilirubin (TSB) reaches gestational-age-specific and hour-specific thresholds, with intensive phototherapy and IV hydration reserved for infants approaching exchange transfusion levels. 1

Initial Assessment and Screening

Universal Pre-Discharge Screening

• Obtain a bilirubin measurement (TSB or transcutaneous bilirubin [TcB]) on all newborns ≥35 weeks gestation before hospital discharge to identify those at risk for severe hyperbilirubinemia and kernicterus 1
• Plot each infant's bilirubin result on an hour-specific nomogram matched to gestational age to determine risk trajectory 1
• Confirm with TSB when TcB is within 3 mg/dL of phototherapy threshold, exceeds the threshold, or is ≥15 mg/dL 1

Risk Factor Identification

Critical risk factors requiring enhanced surveillance include:

• Gestational age <38 weeks (independent risk factor for significant hyperbilirubinemia) 1
• Positive direct antiglobulin test (DAT) indicating hemolytic disease 1
• Suspected or confirmed hemolytic conditions (ABO incompatibility, G6PD deficiency) 1
• Rapid bilirubin rise: ≥0.3 mg/dL per hour during first 24 hours of life, or ≥0.2 mg/dL per hour after 24 hours 1

Diagnostic Workup for Unexplained Jaundice

• Measure G6PD enzyme activity in any infant with unexplained jaundice whose TSB rises despite intensive phototherapy, rises abruptly after initial decline, or needs escalation of care 1

Phototherapy Implementation

Device Specifications

Effective phototherapy requires three critical elements:

• Blue-green wavelength range (460-490 nm), with optimal peak at 478 nm 2
• Irradiance of at least 30 μW/cm²/nm (25-35 μW/cm²/nm minimum) 2
• Illumination of maximal body surface area (35-80% of infant's body) 2

LED light sources are preferred because they deliver specific wavelengths in narrow bandwidths with minimal heat generation 2

Treatment Initiation

• Start phototherapy using gestational-age-specific and hour-specific bilirubin thresholds that incorporate neurotoxicity risk factors 1
• With proper administration, TSB concentrations will decrease within the first 4-6 hours of initiation 2
• Home phototherapy for already-discharged infants can help avoid readmission 2

Safety Monitoring During Treatment

• Assess hydration status and maintain temperature control throughout phototherapy to prevent hyperthermia 1
• Protect IV multivitamins and intralipid infusions from light exposure to avoid oxidant stress and lipid peroxidation 1
• Maintain supine sleep positions for safety; alternating between supine and prone does not reduce phototherapy duration 2
• Phototherapy does not exacerbate hemolysis 2

Discontinuation Criteria

• Ensure TSB has fallen 2-4 mg/dL below the hour-specific treatment threshold before stopping phototherapy 1
• Discontinuing phototherapy as soon as safe reduces unnecessary exposure while minimizing rebound hyperbilirubinemia risk 2

Escalation of Care Protocol

When to Escalate

Initiate escalation protocol when TSB is at or within 0-2 mg/dL below the exchange transfusion threshold 1

Escalation Components

The escalation protocol includes four simultaneous interventions:

• Intravenous hydration to correct any hydration deficit 2, 1
• Emergent intensive phototherapy as soon as possible 2, 1
• Neonatology consultation for possible NICU transfer if TSB continues rising 2, 1
• TSB measurement at least every 2 hours during the escalation period 2, 1

This approach can increase the rate of TSB decline and potentially prevent the need for exchange transfusion 2

Post-Treatment Monitoring

Follow-Up After Phototherapy Discontinuation

High-risk infants (phototherapy started <48 hours of age, GA <38 weeks, positive DAT, or suspected hemolysis):

• Obtain TSB 8-12 hours after discontinuation 1
• Repeat TSB the following day 2, 1

All other infants who received phototherapy:

• Obtain TSB within 1-2 days after discontinuation 2, 1

After 24 hours post-phototherapy:

• TcB may be used as an adjunct instead of TSB 2, 1

Post-Discharge Follow-Up

• High-risk infants should have follow-up within 24-48 hours after discharge (GA <38 weeks, positive DAT, or elevated risk zone at discharge) 1

Parent Education

Teach caregivers to recognize warning signs requiring immediate medical evaluation:

• Poor feeding or deteriorating feeding patterns 1
• Lethargy 1
• High-pitched crying 1
• Fever 1
• Inconsolability, hypotonia, hypertonia, opisthotonus, or retrocollis 2

Critical Pitfalls to Avoid

Measurement Errors

• Never rely solely on visual assessment of jaundice; always obtain objective bilirubin measurement 1
• Do not use TcB alone for treatment decisions when values approach therapeutic thresholds; confirm with serum measurement 1
• TcB measurements are not accurate enough to determine treatment decisions, though both TSB and TcB are good screening tests 2

Treatment Errors

• Do not discontinue phototherapy prematurely; ensure adequate TSB decline below threshold 1
• Do not delay escalation of care when TSB approaches exchange transfusion levels 2

Clinical Impact and Evidence

Recent implementation studies demonstrate that the 2022 AAP guidelines have resulted in:

• 64% reduction in serum bilirubin draws 3
• 51% decrease in phototherapy sessions 3
• 35% reduction in readmissions for phototherapy 3
• No increase in readmission rates or escalation of care 4
• No incidence of bilirubin-induced encephalopathy 4

Decades of phototherapy use in newborns ≥35 weeks gestation has not resulted in clinical evidence of irreversible or serious side effects 2